Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM-124E in Pediatric Nonalcoholic Fatty Liver Disease
NCT03042767Phase 2Completed
- Sponsor
- Miriam Vos
- Start
- Feb 2017
- Primary completion
- Oct 2019
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of IMM-124E in non-alcoholic fatty liver disease (NAFLD), sponsored by Miriam Vos. Started Feb 2017; status: completed.
02
Drugs
IMM-124E
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT03042767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03042767.